OncoArendi Therapeutics SA (WSE:OAT) is a Polish innovative biotechnology company specializing in research, development and commercialization of innovative small molecule drugs for treatment of respiratory diseases and cancer. Researchers at OncoArendi study the role of chitinases and chitinase-like-proteins that provide multiple opportunities for therapeutic interventions. OncoArendi currently has a platform of distinct small molecule programs targeting this classes of proteins, which may have potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. OncoArendi is also focusing on the development of small molecule immune-modulators targeting a key enzyme involved in amino acid metabolism that allows tumor cells to hamper anti-tumor immunity and to avoid immune surveillance. OncoArendi Therapeutics' business model is based on the discovery and development of first-in class or best-in-class small molecules, and then outlicensing its assets to larger pharmaceutical and biotechnology companies. The company has been listed on the WSE main market) since April 2018. More information at www.oncoarendi.com.
Location: Poland, Mazowieckie, Warsaw
Phone: +48 22 552 67 24
Investors 1
| Date | Name | Website |
| - | New Europe... | neweuropev... |
Mentions in press and media 1
| Date | Title | Description |
| 08.02.2022 | OncoArendi Therapeutics is significantly moving closer to the start of a phase one clinical trial for OATD-02 | OncoArendi has received scientific advice from the European Medicines Agency (EMA) on the clinical development of OATD-02 and has signed an agreement with BIOMAPAS for the comprehensive organization of a Phase I clinical trial for the OATD-... |